- Home
- SNOA vs MYNZ Comparison
SNOA vs MYNZ Comparison
Compare SNOA & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNOA
- MYNZ
- Stock Information
- Founded
- SNOA 1999
- MYNZ 2021
- Country
- SNOA United States
- MYNZ Germany
- Employees
- SNOA N/A
- MYNZ N/A
- Industry
- SNOA Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- SNOA Health Care
- MYNZ Health Care
- Exchange
- SNOA Nasdaq
- MYNZ Nasdaq
- Market Cap
- SNOA 6.4M
- MYNZ 5.5M
- IPO Year
- SNOA 2007
- MYNZ 2021
- Fundamental
- Price
- SNOA $2.90
- MYNZ $1.40
- Analyst Decision
- SNOA
- MYNZ Buy
- Analyst Count
- SNOA 0
- MYNZ 2
- Target Price
- SNOA N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- SNOA 25.5K
- MYNZ 120.1K
- Earning Date
- SNOA 06-17-2025
- MYNZ 07-07-2025
- Dividend Yield
- SNOA N/A
- MYNZ N/A
- EPS Growth
- SNOA N/A
- MYNZ N/A
- EPS
- SNOA N/A
- MYNZ N/A
- Revenue
- SNOA $14,288,000.00
- MYNZ $893,991.00
- Revenue This Year
- SNOA $38.54
- MYNZ $26.06
- Revenue Next Year
- SNOA N/A
- MYNZ $4.97
- P/E Ratio
- SNOA N/A
- MYNZ N/A
- Revenue Growth
- SNOA 12.20
- MYNZ N/A
- 52 Week Low
- SNOA $1.75
- MYNZ $1.34
- 52 Week High
- SNOA $9.37
- MYNZ $22.40
- Technical
- Relative Strength Index (RSI)
- SNOA 38.85
- MYNZ 23.25
- Support Level
- SNOA $2.81
- MYNZ $1.34
- Resistance Level
- SNOA $3.45
- MYNZ $1.48
- Average True Range (ATR)
- SNOA 0.13
- MYNZ 0.13
- MACD
- SNOA -0.05
- MYNZ -0.01
- Stochastic Oscillator
- SNOA 10.77
- MYNZ 3.72
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.